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SUMMARY
Neomorphic mutations in NADP-dependent isocitrate dehydrogenases (IDH1 and IDH2) 
contribute to tumorigenesis in several cancers. Although significant research has focused on the 
hypermethylation phenotypes associated with (D)2-hydroxyglutarate (D2HG) accumulation, the 
metabolic consequences of these mutations may also provide therapeutic opportunities. Here we 
apply flux-based approaches to genetically engineered cell lines with an endogenous IDH1 
mutation to examine the metabolic impacts of increased D2HG production and altered IDH flux as 
a function of IDH1 mutation or expression. D2HG synthesis in IDH1-mutant cells consumes 
NADPH at rates similar to de novo lipogenesis. IDH1-mutant cells exhibit increased dependence 
on exogenous lipid sources for in vitro growth, as removal of medium lipids slows growth more 
dramatically in IDH1-mutant cells compared with those expressing wild-type or enzymatically 
inactive alleles. NADPH regeneration may be limiting for lipogenesis and potentially redox 
homeostasis in IDH1-mutant cells, highlighting critical links between cellular biosynthesis and 
redox metabolism.
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Badur et al. apply metabolic flux analysis to understand how oncogenic mutations in IDH1 alter 
redox metabolism. Production of (D)2-hydroxyglutarate (D2HG) consumes NADPH at levels 
similar to de novo lipogenesis, and removal of lipids compromises in vitro growth of IDH1-mutant 
cells.
Graphical Abstract
INTRODUCTION
Mutations in isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) are prevalent in acute myeloid 
leukemias, gliomas, sarcomas, and other tumors (Mardis et al., 2009; Parsons et al., 2008; 
Sjöblom et al., 2006; Yan et al., 2009). These gain-of-function mutations modify the activity 
of IDH1 and IDH2 such that the major reaction catalyzed is the NADPH-mediated reduction 
of a-ketoglutarate (aKG) to (D)2-hydroxyglutarate (D2HG) (Dang et al., 2009; Ward et al., 
2010). In addition, mutant IDH1 and IDH2 exhibit decreased activity for the wild-type (WT) 
reaction, which reversibly interconverts isocitrate and NADP+ with aKG, CO2, and NADPH 
(Ward et al., 2010). Therefore, cells harboring such IDH mutations exhibit metabolic 
reprogramming to compensate for these changes in enzyme activity.
Under hypoxic conditions, IDH1-mutant cells exhibit increased oxidative TCA flux, 
respiration, and decreased growth (Grassian et al., 2014). Although IDH1-mutant cells do 
not increase reductive carboxylation in hypoxia to the same extent as cells expressing only 
WT IDH1, mitochondrial metabolism and redox pathways are rewired to support the growth 
of mutant IDH1 cells in culture and in vivo (Carbonneau et al., 2016; Fack et al., 2017). 
More generally, IDH1-mutant cells exhibit various defects in mitochondrial metabolism, 
which may be therapeutically exploited by targeting NAMPT, BCL2, or other targets (Chan 
et al., 2015; Izquierdo-Garcia et al., 2015; Seltzer et al., 2010; Tateishi et al., 2015). These 
results demonstrate that IDH1-mutant cells exhibit similar metabolism to cells expressing 
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WT IDH1 under basal conditions but altered metabolic states under conditions of 
bioenergetic or redox stress.
IDH1 is not thought to be a major source of NADPH in mammals (Fan et al., 2014). 
IDH1−/−mice exhibit phenotypes only in select tissues or in response to specific stresses 
(i.e., nutrient deprivation) (Ye et al., 2017). In culture, overall IDH-mediated exchange flux 
is high, and the reverse reaction can support lipogenesis or compartment-specific redox 
maintenance in cancer cells under conditions of metabolic stress (Jiang et al., 2016; Metallo 
et al., 2011; Wise et al., 2011). The oxidative pentose phosphate pathway (oxPPP) is 
classically thought to be the primary pathway through which NADPH is regenerated in the 
cytosol (Stincone et al., 2015). Recent studies using 2H tracing support this concept, 
whereby the oxPPP exhibits the highest contribution to cytosolic NADPH regeneration 
supporting biosynthesis(Zhang et al., 2016, 2017). Cell lines engineered to express mutant 
IDH1 enzymes exhibit increased oxPPP flux and differential lipid synthesis (Gelman et al., 
2018), highlighting the importance of this pathway. On the other hand, knockout of oxPPP 
enzymes is particularly deleterious for cancer cell growth (Zhao et al., 2018).
To better understand how mutations in IDH1 influence NADPH metabolism, we applied 13C 
and 2H metabolic flux analysis to an isogenic panel of fibrosarcoma cell lines that 
endogenously express IDH1+/R132C or were engineered to express a WT, R132C mutant, or 
enzymatically dead IDH1 enzyme after knocking out the original mutant allele (Ma et al., 
2015). These cell lines recapitulate changes in anchorage-independent growth driven by 
mutant IDH1 (Ma et al., 2015) as well as the metabolic defects documented to occur under 
hypoxia. 2HG production and secretion were a major sink of NADPH in IDH1+/R132C cells, 
though cells could sufficiently compensate by modulating oxPPP flux. However, in lipid-
deficient conditions D2HG production and secretion presented a metabolic liability that 
negatively affected de novo lipogenic flux and in vitro cell growth. These results 
demonstrate that IDH1 R132 mutations may be considered a significant redox liability in 
tumors, rendering them susceptible to metabolic stress.
RESULTS
Use of Genetically Engineered HT1080 Fibrosarcoma Cell Lines to Dissect Enzymatic 
Functions of IDH1 and Mutant IDH1
D2HG production in cells harboring R132 mutations in IDH1 is dramatically increased and 
has an established role in 
tumorigenesis.Hereweinterrogatedredoxmetabolismoffibrosarcomacells using a genetically 
engineered panel of cell lines that recapitulate the metabolic reprogramming associated with 
oncogenic IDH1 mutations. In this system, the mutant IDH1 allele was knocked out of 
HT1080 fibrosarcoma cells (+/R132C), generating HT1080 cells heterozygous cell line for 
IDH1 (+/-). Next, an isogenic IDH1-mutant panel was then re-expressed in the HT1080 
IDH1 (+/-) cell line generating vector control (PB; +/-), engineered WT IDH1 (+/+), re-
expressed IDH1-mutant (R132C; +/R132C), and catalytically dead double-mutant (T77A; +/ 
R132C-T77A) cell lines (Ma et al., 2015). As depicted in Figure 1A, these cell lines exhibit 
distinct reprogramming of IDH1 enzymatic activity such that PB and WT cells maintain 
endogenous activity and do not readily produce D2HG, R132C mutants have reduced 
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endogenous IDH1 activity and produce D2HG, while T77A mutants have reduced 
endogenous IDH1 activity and do not accumulate D2HG(Maetal.,
2015).Therefore,wecouldinterrogatethedistinct metabolic consequences of modulating WT 
IDH1 activity as well as neomorphic D2HG production by IDH1 R132C.
We first quantified per cell organic and amino acid abundances in each cell type, observing 
R132C-specific changes in abundance of glutamine and aKG (Figure 1B). In addition, we 
detected increased levels of non-essential amino acids (i.e., Glu, Ser, Pro, and Asp), 
consistent with previously described increases in glutaminolysis in IDH1-mutant cells 
(Grassian et al., 2014; Seltzer et al., 2010). We also observed elevated levels of Gly3P in 
R132C cells, suggesting that mitochondrial and/or cytosolic redox metabolism is perturbed 
in D2HG-producing cells (Figure 1B). On the other hand, intracellular abundance of most 
glycolytic metabolites, TCA metabolites, and other amino acids were not perturbed by 
altered IDH1 enzymatic function (Figure 1B). These results are consistent with general 
dispensability of IDH1 function in basal culture conditions.
Next, we characterized alterations in IDH flux in this isogenic fibrosarcoma cell line panel. 
Under conditions of hypoxia, IDH1 and IDH2 can support de novo lipogenesis by catalyzing 
the reductive carboxylation of aKG to isocitrate, which is subsequently metabolized to 
citrate and acetyl-coenzyme A (AcCoA) (Metallo et al., 2011). Cells harboring IDH1 
mutations are defective in their ability to convert glutamine carbon to citrate and AcCoA 
(Grassian et al., 2014). To this end, we cultured each HT1080 cell line in the presence of 
uniformly labeled 13C glutamine ([U-13C5]glutamine) and quantified the isotopologue 
distribution of metabolites in central carbon metabolism (Figure 1C). We observed a 
significant decrease in M+5 citrate in R132C cells cultured in hypoxia compared with those 
expressing only functional WT IDH1, indicating that R132C-expressing cells were limited 
in their ability to generate citrate via reductive carboxylation (Figures 1D and S1A). We also 
observed a concomitant increase in M+4 citrate in R132C cells, consistent with previously 
described reliance of IDH1-mutant cells on oxidative glutaminolysis in hypoxia (Figures 
S1A and S1B; Grassian et al., 2014). We also observed altered labeling of aspartate from 
[U-13C5]glutamine that is consistent with decreased reductive carboxylation flux for 
generating cytosolic AcCoA (Figures 1E and S1C). This isogenic panel of HT1080 cells 
therefore recapitulates hallmarks of cancer cells expressing oncogenic IDH1 mutations. 
Notably, WT IDH1 cells had the highest abundance of M+5 citrate and M+3 aspartate 
isotopologues, while PB and T77A cells (which have only one WT IDH1 allele) had 
intermediate levels of these isotopologues (Figures 1D and 1E).
Cytosolic NADPH Contributes to D2HG Production from IDH1+/R132c Cells
Basal IDH1 enzymatic function can facilitate both production and consumption of NADPH 
and is decreased in IDH1-mutant cells (Geisbrecht and Gould, 1999; Ward et al., 2010; Zhao 
et al., 2009), suggesting that cellular redox may be perturbed in these cells. To this end, we 
also observed elevated levels of Gly3P in R132C cells (Figure 1B). To investigate how redox 
metabolism is altered by IDH1 mutation, we cultured cells in the presence of [4-2H]glucose 
and quantified enrichment on downstream metabolites (Figure 2A). This tracer specifically 
labels cytosolic NADH via GAPDH, and these deuterons are subsequently transferred to 
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lactate, malate, and Gly3P by downstream oxidoreductases (Lewis et al., 2014). We 
observed similar labeling in all cells tested (Figure 2B), indicating that no gross changes in 
NAD+ regeneration occurred upon perturbation of IDH1 activity.
We next examined how NADPH metabolism is altered in these HT1080 cell lines, as D2HG 
production by R132C IDH1 relies on the NADPH-dependent reduction of aKG. As NADPH 
and NADH pools are interconnected through transhydrogenase shuttles and enzymes 
(Cracan et al., 2017), the redox pathways that support 2HG production are not well 
understood. Indeed, D2HG accumulates to high millimolar intracellular concentrations in 
IDH-mutant cells (Dang et al., 2009), and we observed a drastic increase in intracellular 
2HG only in R132C cells (Figure 2C). However, we also detected low levels of 2HG in cell 
lines expressing only WT IDH1 or enzymatically dead R132C-T77A IDH1 and 
hypothesized that L2HG was endogenously produced in these cells. To investigate the 
enantiomer of 2HG and source of reducing equivalents used for 2HG production in these 
cell lines, we cultured each cell type with [4-2H]glucose or [3-2H] glucose, which label 
NADH and NADPH respectively, and quantified 2HG labeling via gas chromatography-
mass spectrometry (GC-MS) (Lewis et al., 2014). Results were distinct in that [4-2H] 
glucose labeled approximately 10% of 2HG in PB, WT, and T77A cells, while 
[3-2H]glucose labeled ~15% of 2HG in R132C cells (Figure 2D). These data suggest that 
L2HG is the predominant enantiomer present in cells expressing only WT IDH1, which has 
been demonstrated to be a byproduct of lactate dehydrogenase (LDH), malate 
dehydrogenase (MDH), or phosphoglycerate dehydrogenase (PHGDH) in cancer cells 
(Figure 2E; Fan et al., 2015; Intlekofer et al., 2015, 2017). Notably, 2HG enrichment from 
[3-2H]glucose was similar to the expected enrichment of cytosolic NADPH calculated from 
fatty acid labeling (Figure 3C; Lewis et al., 2014). L2HG enrichment was significantly lower 
than that observed for lactate, malate, and Gly3P, suggesting that some 2HG is present in 
cells with WT IDH1. Ultimately, these results highlight the utility of deuterium tracing in 
assessing redox metabolism associated with altered IDH1 metabolism.
2HG Production Contributes Significantly to Cellular NADPH Demands
We next attempted to estimate how D2HG production and other pathways contribute to 
NADPH demands within cells by quantifying 2HG secretion flux. De novo lipogenesis 
(DNL) has been estimated to be the largest consumer of NADPH in cultured cells (Fan et al., 
2014). We measured DNL flux for fatty acid and cholesterol synthesis using 
[1,2-13C2]glucose and isotopomer spectral analysis and compared the NADPH requirements 
for DNL and 2HG (Figure 3A). Strikingly, we found that the NADPH demand for D2HG 
production was relatively similar to that required for DNL (Figure 3A). Importantly, most 
D2HG-associated NADPH consumption was from the efflux of D2HG. This increased 
NADPH demand did not affect palmitate synthesis in R132C cells at early time points in 
culture (Figure S2A). However, we did observe an increased uptake of [13C]palmitate from 
culture medium specifically in R132C cells, suggesting a potential reprogramming of lipid 
metabolism (Figure S2B).
We then asked if the consumption of NADPH by D2HG production influenced redox 
pathways associated with NADPH regeneration. The largest source of cytosolic NADPH in 
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cells is the oxPPP (Zhang et al., 2017). To probe any alterations in oxPPP redox function, we 
used a modeling approach to estimate the fraction of lipogenic NADPH supplied by the 
oxPPP (Figure 3B; Lewis et al., 2014). Despite the increased R132C-specific consumption 
of NAPDH by D2HG production, we found no change in the relative proportion of NADPH 
supplied by the oxPPP across these cell lines (Figure 3C). We also observed no alteration in 
the balance of flux (i.e., pathway activity) diverted to the oxPPP and non-oxPPP to both 
glycolytic intermediates (Figure S2C) and biomass-derived ribose (Figures S2D and S2E), 
indicating that cells were able to compensate for D2HG synthesis by increasing lipid uptake 
only.
To control for any clonal effects associated with production of the cell line panel, we then 
inhibited D2HG production in the parental HT1080 cell line using AGI-5198, a 
pharmacological inhibitor of mutant IDH1 (Rohle et al., 2013). We observed a~90% 
reduction in 2HG/aKG levels with AGI-5198 addition, implying a reduction in NADPH 
consumption by D2HG production (Figure 3D). However, inhibition of NADPH 
consumption did not alter NADPH supplied by oxPPP (Figure 3E). Taken together our data 
indicate that D2HG production does not alter the contribution of oxPPP flux to redox 
homeostasis, as cells are able to sufficiently rewire pathways to compensate for the increased 
NADPH demand. Indeed, we also quantified the contribution of oxPPP flux to lipogenic 
NADPH using engineered HCT116 cells with knockin of mutant IDH1. IDH1+/R132H 
HCT116 cells exhibited increased contributions of oxPPP to lipogenic NADPH pools 
(Figure 3F), highlighting the ability of cells to reprogram redox pathways to meet the 
increased demands for NADPH caused by oncogenic D2HG production.
DNL Competes with D2HG Production for NADPH
Our results suggest that R132C cells are able to compensate for NADPH consumed by 
D2HG production under normal growth conditions. However, this metabolic defect could 
become a liability in the context of altered nutrient conditions. Recent work has 
demonstrated the utility in altering extracellular nutrient conditions to understand cancer-
specific metabolic liabilities and sparked an interest in engineering more physiologic media 
(Cantor et al., 2017). The tumor microenvironment is generally considered to be nutrient 
deficient, and tumor cells upregulate DNL to synthesize lipids necessary for growth 
(Ackerman and Simon, 2014). Indeed, lipogenesis is necessary for in vitro and in vivo tumor 
growth, and limitations in this pathway renders tumor cells more susceptible to 
chemotherapeutics (Svensson et al., 2016). To this end, we hypothesized that removal of 
exogenous lipids from cell culture media could alter R132C-specific growth by limiting the 
NADPH available for DNL flux. We observed that R132C cell growth was specifically 
decreased in delipidated culture conditions (Figure 4A). We also confirmed this growth 
phenotype in human oligodendroglioma (HOG) cells that ectopically express mutant IDH1 
(Figures 4B and S3A). We then found that R132C cells exhibited decreased molar palmitate 
synthesis flux, suggesting the observed growth defect was mediated by an inability to 
synthesize enough lipids (Figure 4C).
We then asked what specific metabolic liability could be causing DNL defect in R132C 
cells. DNL is critical biosynthetic process that requires the coordination of many enzymes 
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and sufficient anabolic substrates (i.e., AcCoA and NADPH). As many possible factors 
could decrease DNL, we investigated potential drivers of this observed growth defect 
(Figure 4A). 2HG has been widely characterized as an inhibitor of aKG-dependent 
dioxygenase class enzymes that include important epigenetic modifiers (i.e., demethylases) 
(Figueroa et al., 2010; Lu et al., 2012; Turcan et al., 2012; Xu et al., 2011). We observed that 
expression of genes associated with fatty acid synthesis was not altered in R132C cells, 
implying that the production of D2HG, rather than a downstream epigenetic modification, 
caused the growth defect (Figure S3B). We also observed no alteration in the contribution of 
oxPPP flux to lipogenic NADPH, indicating that other redox pathways were not distinctly 
compensating (Figure S3C). We detected a slight increase in glucose contribution to 
lipogenic AcCoA, consistent with 2HG production shunting glutamine carbon away from 
DNL (Figure S3D). We also observed a concomitant increase in glutamine uptake in R132C 
cells cultured under delipidated conditions that could support 2HG production without 
limiting carbon for DNL (Figure S3D). Alterations in glutamine metabolism independent of 
2HG production were observed in T77A double-mutant cells (Figure S3D), consistent with 
altered central carbon metabolite abundance (Figure S3E). Further work must be done to 
understand how loss of WT IDH1 enzymatic activity reprograms metabolism to support 
DNL. Taken together, these changes are unlikely to account for the altered cell growth in 
delipidated conditions.
On the other hand, the desaturation index (C18:1/C18:0) quantified from total fatty acids in 
each cell line was significantly decreased in R132C cells (Figure 4D). Production of 
desaturated fatty acid species requires SCD activity, molecular oxygen, and NADPH 
(Kamphorst et al., 2013; Young et al., 2013). Because we did not detect changes in SCD 
expression (Figure S2B) and molecular oxygen is not limiting under normoxic conditions, 
this result suggests that NADPH was limiting R132C cells and could explain the decreased 
palmitate synthesis observed in R132C cells (Figure 4B). Importantly, we observed a 
dramatic increase in cholesterol biosynthesis with serum delipidation (Figure 4E). The 
NADPH requirements for cholesterol synthesis (26 molecules per cholesterol molecule) is a 
significant biosynthetic sink for NADPH, highlighting the importance of both fatty acid and 
sterol synthesis in contributing to the redox needs of proliferating cancer cells.
To better understand how NADPH regeneration fluxes were altered, flux through glycolysis 
and the oxPPP were quantified across the cell panel. We observed increased glycolytic 
fluxes in both R132C and T77A cells compared with WT (Figure 4F). Increased glycolytic 
flux is generally associated with altered mitochondrial state, but our data suggest that 
mitochondrial pathways are maintained by reprogramming of glutamine metabolism 
(Grassian et al., 2014). However, increased glucose uptake can also result in elevated oxPPP 
flux if branching is unchanged. We cultured cells in the presence of [1,2-13C]glucose tracer 
to understand the relative shunting of glucose carbon through glycolysis and the oxPPP (Lee 
et al., 1998). We observed no difference in relative shunting to the oxPPP across the cell 
lines (Figure S2G). However, when combined with the increased glucose uptake and lactate 
efflux detected in R132C cells, these data indicate that oxPPP activity is significantly 
increased to meet the additional NADPH demands for D2HG production (Figure 4G). 
Importantly, R132C cells increase glucose uptake and oxPPP flux to a greater extent than 
T77A cells, implying that oxPPP flux and NADPH production is further increased to support 
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D2HG production (Figure 4G). In turn, the cells are unable to fully compensate for these 
NADPH demands and growth is reduced in lipid-deficient conditions.
Finally, we investigated whether pharmacological inhibition of 2HG production by 
AGI-5198 could alter growth in delipidated conditions. Administration of AGI-5198 in vitro 
did not improve growth under such conditions and slightly decreased cell growth (Figure 
S4A). Additionally, inhibition of 2HG production by AGI5198 did not alter the desaturation 
index of cellular fatty acids, suggesting that NADPH availability was not sufficiently altered 
(Figure S4B). As AGI-5198 does not completely block 2HG production at concentrations 
routinely used in vitro and could also inhibit WT enzyme activity (Figure 3D), further 
studies are needed to understand how inhibition of mutant IDH1 might influence the redox 
sensitivity of tumor cells in the context of combinatorial treatments.
DISCUSSION
The unique nature of IDH-mutant tumors has motivated a large research effort to identify 
potential targets within their signaling and metabolic networks (Chaumeil et al., 2013; 
Salamanca-Cardona et al., 2017; Turcan et al., 2018; Venteicher et al., 2017). The dramatic 
accumulation of 2HG in these tumors has focused much attention on the role of aKG-
dependent dioxygenases in driving tumorigenesis (Losman and Kaelin, 2013). However, as 
IDH1 and IDH2 play critical roles in TCA metabolism and redox homeostasis, a greater 
understanding of the metabolic reprogramming required to support this unique liability may 
yield clues to additional therapeutic opportunities (Parker and Metallo, 2015). Such 
metabolic alterations could explain why genetic disruption of mutant IDH1 affects the 
growth of some cells but not pharmacological inhibition (Jin et al., 2012, 2013).
Maintenance of redox homeostasis is essential for proper cell function, as pyridine 
nucleotides orthogonally connect bioenergetic and biosynthetic metabolic pathways (Badur 
and Metallo, 2018). Specifically, the regeneration of NADPH is required for anabolism of 
lipids, DNA, and proline as well as maintenance of reduced glutathione pools (Fan et al., 
2014). However, the role of IDH1 in the maintenance of redox homeostasis has been 
underappreciated. IDH1 can functionally participate in a redox shuttle that interconnects 
mitochondrial and cytosolic NAD(P)H pools (Sazanov and Jackson, 1994). Indeed, this 
shuttle has been demonstrated to be critical for redox homeostasis in anchorage-independent 
conditions (Jiang et al., 2016). Upregulation of IDH1 can promote the survival of pancreatic 
cancer cell lines under nutrient-limited conditions (Zarei et al., 2017). However, the largest 
source of NADPH in the cell is the oxPPP (Fan et al., 2014; Lewis et al., 2014; Zhang et al., 
2017). Targeting of oxPPP enzymes is particularly deleterious to growth of cancer cell lines 
(Lin et al., 2015; Rao et al., 2015; Zhao et al., 2018), and coordinated therapeutic strategies 
that induce redox stress (e.g., nutrient modulation, radiation) while inhibiting pathways that 
promote redox homeostasis may be particularly effective (Conklin, 2004). Specifically, we 
highlight the importance of exogenous lipid availability in influencing cellular redox 
pathways, such that the increased NADPH requirements for fatty acid and sterol synthesis 
compromise growth of cell lines expressing mutant IDH1.
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Our work suggests that IDH1-mutant tumor cells may be susceptible to therapeutic strategies 
that promote oxidative stress (albeit in cell culture); however, more extensive testing in 
animals is required to realize the translational potential of such approaches. We found that 
D2HG production is a major sink for NADPH, which is needed for reductive biosynthesis 
and redox homeostasis. When cells are challenged by lipid deficiency that drives cells to 
upregulate DNL flux, D2HG production becomes a metabolic liability that limits growth. 
Similar findings have recently been reported using engineered HCT116 cells (Gelman et al., 
2018). Other pathways have also been described to compensate for such redox defects. For 
example, IDH1 mutant glioma cells maintain redox homeostasis by enhancing the 
mitochondrial production of proline (Hollinshead et al., 2018). Metabolic profiling of low-
grade gliomas has also correlated tumor progression with altered redox state (Jalbert et al., 
2017). Additional studies are needed to understand if this redox sensitivity can be exploited 
in vivo. Recent work has demonstrated that D2HG can inhibit branched-chain amino acid 
transaminases (BCATs), compromising glutathione synthesis and sensitizing tumors to 
radiotherapy in combination with glutaminase inhibition (McBrayer et al., 2018). Such 
studies reinforce the concept that IDH mutations can reprogram the metabolic network to 
sensitize tumors to combinatorial therapies. Our studies highlight the importance of reducing 
equivalent availability in lipid biosynthesis. Although DNL is required for growth of lung 
tumors as xenografts or in genetically engineered mouse models (Svensson et al., 2016), the 
lipogenic requirements of sarcomas, gliomas, and other IDH1-mutant tumors may be 
different. Furthermore, the impact of dietary fat and combination therapies using mutant 
IDH1 inhibitors and/or radiation must be considered to appreciate the therapeutic potential 
of these findings. Nevertheless, our results highlight the impact of lipogenesis and D2HG 
production on cellular redox pathways.
STAR⋆METHODS
KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Chemicals, Peptides, and Recombinant 
Proteins
[1,2-13C]glucose Cambridge Isotope Labs CLM-504
[3-2H]glucose Omicron Biochemicals GLC-034
[4-2H]glucose Omicron Biochemicals GLC-035
[U-13C6]glucose Cambridge Isotope Labs CLM-1396
[U-13C5]glutamine Cambridge Isotope Labs CLM-1822
Critical Commercial Assays
RNeasy Mini Kit QIAGEN 74104
cDNA Reverse Transcription Kit Thermo Fisher Scientific 4368814
Cyquant Cell Proliferation Assay Thermo Fisher Scientific C7026
Experimental Models: Cell Lines
HCT116 parental and IDH1 knock-in clones 
(2H1, 2A9)
Horizon Discovery N/A
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REAGENT or RESOURCE SOURCE IDENTIFIER
HT1080 ATCC N/A
HT1080 IDH1 panel Ma et al. (2015) https://doi.org/10.18632/oncotarget.3330
Human oligodendroma IDH1 panel McBrayer et al. (2018) https://doi.org/10.1016/j.cell.2018.08.038
Oligonucleotides
RT-PCR primers, see Table S2 Primerbank N/A
Software and Algorithms
INCA Young (2014) https://mfa.vueinnovations.com/
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Christian Metallo (cmetallo@ucsd.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines and Culture Conditions—HT1080 and HCT116 cells were grown in 
DMEM supplemented with 10% FBS and 100 U/mL penicillin/streptomycin. HOG cells 
were grown in IMDM supplemented with 10% FBS, 100 U/mL penicillin/streptomycin, and 
200 μg/mL hygromyocin (McBrayer et al.). HT1080 parental cells were obtained from 
ATCC. HCT116 parental and IDH1 knock-in clones (+/R132C; 2H1 and 2A9) were 
obtained from Horizon Discovery. Cells were maintained in humidified incubator at 5% 
CO2. For hypoxia experiments, cells were maintained in humidified glove box (Coy) at 5% 
CO2 and 1% O2.
METHOD DETAILS
Cell growth and stable isotope tracing—For delipidated cell growth experiments, 
cells were plated in basal media. Fibrosarcoma cells were then allowed to adhere for 4 hours 
and then media was exchanged to delipidated media. HOG cells were allowed to adhere 
overnight and then media was exchanged to delipidated media. Cell growth was measured 
by either using hemocytometer for final cell counts or using Cyquant Cell Proliferation 
Assay (Molecular Probes) for estimation of DNA abundance, per manufacturer’s protocol.
For isotopic labeling experiments, cells were plated in basal growth experiments and then 
rinsed with PBS before addition of tracing media. Cells were cultured in glucose- and 
glutamine-free media (GIBCO) supplemented with 10% dialyzed FBS, 100 U/mL penicillin/
streptomycin, 4mM glutamine, and 25mM glucose. For glutamine tracing, cells were 
supplied 12C glucose (Sigma) and [U-13C5]glutamine (99%, Cambridge Isotope 
Laboratories). For glucose tracing, cells were supplied 12C glutamine (Sigma) and either 
[3-2H]glucose (99%, Cambridge Isotope Laboratories), [4-2H]glucose (99%, Omicron 
Biochemicals), [U-13C6] glucose (99%, Cambridge Isotope Laboratories), or 
[1,2-13C]glucose (99%, Cambridge Isotope Laboratories). For palmitate uptake, 
[U-13C16]palmitate (99%, Cambridge Isotope Laboratories) was bound to fatty-acid free 
albumin (Roche) as previously described and supplied to cells at 50 μM (5% v/v) (Vacanti et 
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al., 2014). For delipidated tracing experiments, media was prepared in same way except 
using 10% dialyzed and delipidated FBS.
Delipidation of FBS—Normal or dialyzed FBS (GIBCO) was delipidated by first stirring 
20 mg/mL fumed silica (Sigma) for 3 hr in ambient conditions. FBS slurry was then clarified 
by repeated centrifugation at 2000 g for 20 min. Supernatant was then sterile filtered (0.2 
mm), aliquoted, and stored at _20C for future use.
Metabolite Extraction and GC-MS Analysis—Cells were rinsed with 0.9% (w/v) 
saline and 250 μL of —80⁰C MeOH was added to quench metabolic reactions. 100 μL of 
ice-cold water supplemented with 10 μg/mL norvaline was then added to each well and cells 
were collected by scraping. The lysate was moved to a fresh 1.5 mL sample tube and 250 μL 
of —20⁰C chloroform supplemented with 4 μg/mL D31 palmitate (and 4 μg/mL 
coprostan-3-ol if quantifying cholesterol) was added. After vortexing and centrifugation, the 
top aqueous layer and bottom organic layer were collected and dried under airflow. For 
analysis of cellular biomass, remaining interfacial layer was isolated, washed twice with 
methanol, and allowed to dried overnight with ambient airflow (Badur et al., 2015).
Derivatization of aqueous metabolites was performed using the Gerstel MultiPurpose 
Sampler (MPS 2XL). Methoxime- derivatives were formed by addition of 15 μL 2% (w/v) 
methoxylamine hydrochloride (MP Biomedicals) in pyridine and incubated at 45C for 60 
minutes. Samples were then silylated by addition of 15 mL of N-tert-butyldimethylsily-N-
methyltrifluoroacetamide (MTBSTFA) with 1% tert-butyldimethylchlorosilane (tBDMS) 
(Regis Technologies) and incubated at 45⁰C for 30 minutes. Aqueous metabolites were 
analyzed by GC-MS using a DB-35MS column (30 m x 0.25mm i.d. x 0.25 mm, Agilent 
J&W Scientific, Santa Clara, CA) installed in an Agilent 7890B gas chromatograph (GC) 
interfaced with a 5977C mass spectrometer (MS). For separation of aqueous metabolites, the 
GC oven was held at 100⁰C for 1 min after injection, increased to 255⁰C at 3.5⁰C/min, and 
finally increased to 320⁰C at 15⁰C/min and held for 3 min. Electron impact ionization was 
performed with the MS scanning over the range of 100–650 m/z.
Dried organic fraction was saponified and esterified to form fatty acid methyl esters 
(FAMEs) by addition of 500 μL of 2% (w/v) H2SO4 in MeOH and incubated at 50⁰C for 
120 minutes. FAMEs were then extracted by addition of saturated NaCl and hexane before 
collection and drying of the inorganic layer. Derivatized fatty acids were analyzed by GC-
MS using a select FAME column (100 m x 0.25mm i.d. x 0.25 μm; Agilent J&W Scientific) 
installed in an Agilent 7890A gas chromatograph (GC) interfaced with a 5975C mass 
spectrometer (MS). For separation the GC oven was held at 80⁰C for 1 min after injection, 
increased to 160⁰C at 20⁰C/min, increased to 198⁰C at 1⁰C/min, and finally increased to 
250⁰C at 5⁰C/min and held for 15 min. Electron impact ionization was performed with the 
MS scanning over the range of 120–400 m/z. For cholesterol measurements, saponified 
organic phase was then redried under airflow and derivatized using a Gerstel autosampler by 
addition of 15 μL of N-methyl-N-trimethylsilyl-trifluoroacetamide (MSTFA; 
MachereyNagel) and incubated at 45⁰C for 30 minutes. Cholesterol was was analyzed by 
GC-MS using a DB-35MS column (30 m x 0.25mm i.d. x 0.25 μm, Agilent J&W Scientific, 
Santa Clara, CA) installed in an Agilent 7890B gas chromatograph (GC) interfaced with a 
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5977C mass spectrometer (MS). For separation, the GC over was held at 150⁰C for 1 min 
after injection, increased to 260⁰C at 20⁰C/min and held for 3 min, and then increased to 
280⁰C at 10⁰C/min and held for 15 min. Electron impact ionization was performed with the 
MS scanning over the range of 70–800 m/z.
Cellular biomass was hydrolyzed with 2N HCl for 2 hr at 80⁰C to release ribose monomers 
and then dried under airflow. Dried samples were then dissolved in 200 μL 2% (w/v) 
hydroxylamine hydrochloride in pyridine (Sigma) and incubated at 90C for 60 min. Next, 
100 μL of propionic anhydride was added and samples were incubated at 60⁰C for 30 min. 
Samples were then evaporated under airflow at 60⁰C and resuspended in 100 μL ethyl 
acetate. Aldonitrile pentapropionate derivatives were then analyzed by GC-MS using a 
DB-35MS column (30 m x 0.25mm i.d. x 0.25 μm, Agilent J&W Scientific, Santa Clara, 
CA) installed in an Agilent 7890B gas chromatograph (GC) interfaced with a 5977C mass 
spectrometer (MS). For separation, the GC over was held at 100⁰C for 1 min after injection 
and then increased to 255⁰C at 20⁰C/min and held for 4 min. Electron impact ionization was 
performed with the MS scanning over the range of 120–650 m/z.
Metabolite integration and isotopomer spectral analysis (ISA)—Isotopologue 
distributions and total abundances were determined by integration of mass fragments (Table 
S1) and correcting for natural abundances using in-house MATLAB-based algorithm.
Isotopomer spectral analysis (ISA) was performed to estimate contribution of oxPPP to 
cytosolic NADPH as previously described (Lewis et al., 2014). ISA compares experimental 
labeling of palmitate after 72 hr trace with [3-2H]glucose to simulated labeling using a 
reaction network where C16:0 is condensation of 14 NADPHs. Parameters for contribution 
of PGD to lipogenic NADPH (D value) and percentage of newly synthesized fatty acid (g(t) 
value) and their 95% confidence intervals are then calculated using best-fit model from 
INCA MFA software (Young, 2014). Contribution of oxPPP was then estimated by doubling 
D value to account for stoichiometry of the oxPPP pathway.
Estimation of contribution of 13C tracers to lipogenic AcCoA and palmitate synthesis was 
conducted as similar method to oxPPP contribution. Experimental fatty acid labeling from 
[U-13C6]glucose, [U-13C5]glutamine, or [1,2-13C]glucose after 24–72 hr trace was compared 
to simulated labeling using a reaction network where C16:0 is condensation of 8 AcCoA. 
ISA data plotted as mean ± 95% CI. * indicates statistical significance by non-overlapping 
confidence intervals.
Estimation of cholesterol synthesis was similarly conducted. Experimental cholesterol 
labeling from [1,2-13C]glucose or [U-13C5] glutamine after 24 hr trace was to compared to 
simulated labeling using a previously described reaction network (Kelleher et al., 1994). ISA 
data plotted as mean ± 95% CI.
Measurement of extracellular and intracellular fluxes—Initial and final 
concentrations of extracellular glucose, lactate, glutamine, and glutamate were determined 
by Yellow Springs Analyzer 2950 instrument. In parallel, cells were plated for initial and 
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final cell counts. Plated cells were pre-adapted to delipidated DMEM media for 24 hr before 
experiment.
The extracellular fluxes were described by the following differential equations:
dX
dt = μX
dNi
dt = qiX
dNgln
dt = qiX − kNgln
where, X is concentration of cells, m is cellular growth (hr−1), N is extracellular moles of 
metabolite i present, qi is cell-specific consumption rate of metabolite i (mol/cell-hr), and k 
is first-order degradation rate of glutamine in cell culture (hr−1). k was set to 0.0045 hr−1 as 
determined in literature (Tritsch and Moore, 1962).
Solution of ODEs yielded the following equations which we used to find extracellular 
fluxes:
X = X0e
μt
qi =
μ Ni − Ni, 0
X − X0
qgln =
Ngln − Ngln, 0e
−kt
1
μ + k X − X0e
−kt
where subscript 0 signifies initial concentration.
For oxPPP measurement, glucose uptake measurement was coupled to ratio of (M1/(M1 + 
M2)) lactate label from [1,2-13C] glucose tracer. This measurement is only appropriate when 
(1) considering relative differences across similar experimental conditions and (2) assuming 
that non-oxPPP flux and biosynthetic demands of ribose are not altered between conditions.
NADPH consumption—For fatty acid synthesis, consumption was defined as NADPH 
flux required to support biosynthesis of myristate (C14:0), palmitate (C16:0), stearate 
(C18:0), and oleate (C18:1) as these are predominantly synthesized species (Fan et al., 
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2014). Cells were traced with [1,2-13C]glucose for 24 hr and extracted for intracellular 
metabolites. In parallel, initial and final cell counts were taken. Per cell molar abundance of 
fatty acid species was determined by GC/MS. Percentage newly synthesized fatty acid was 
determined by ISA with reaction network where C14:0 is condensation of 7 AcCoA, C16:0 
is condensation of 8 AcCoA, C18:0 is condensation of 9 AcCoA, and C18:1 is condensation 
of 9 AcCoA. Molar fatty acid synthesis flux was then calculated by dividing molar newly 
synthesized fatty acids by integral viable cell density over experimental time period. 
NADPH flux was then calculated by stoichiometric requirement of 12 NADPH per 
myristate, 14 NADPH per palmitate, 16 NADPH per stearate, and 17 NADPH per oleate.
For cholesterol, percentage newly synthesized was determined by ISA as stated above. 
Molar cholesterol synthesis flux was then calculated by dividing molar newly synthesized 
cholesterol by integral viable cell density over experimental time period. NADPH flux was 
then calculated by stoichiometric requirement of 26 NADPH per cholesterol.
For 2HG production fluxes, consumption was defined as NADPH flux required to support 
2HG efflux and maintenance of intracellular abundance. Initial and final concentrations of 
extracellular 2HG were determined by GCMS analysis and use of external standard curves. 
Per cell molar abundance of 2HG was determined by GCMS at final time point. Efflux was 
then calculated similarly as above and dilutive flux was calculated by dividing intracellular 
concentration by specific growth rate. NADPH flux was then calculated by stoichiometric 
requirement of one NADPH per 2HG.
RT-PCR—Total mRNA was isolated from cells using RNA isolation kit (RNeasy Mini Kit; 
QIAGEN). Isolated RNA was reverse transcribed using cDNA synthesis kit (High-capacity 
cDNA Reverse Transcription Kit; Thermo Fisher Scientific). Real-time PCR was performed 
using SYBR green reagent (iTaq Universal SYBR Green Supermix; Bio-Rad). Relative 
expression was determined using Livak (ΔΔCT) method with GAPDH as housekeeping 
gene. Primers used were taken from Primerbank (Wang et al., 2012) and tabulated in Table 
S2. All commercial kits were used per the manufacturer’s protocol.
QUANTIFICATION AND STATISTICAL ANALYSIS
Unless indicated, all results shown as mean ± SEM of biological triplicates. P values were 
calculated using a Student’s two-tailed t test; *, P value between 0.01 and 0.05; **, P value 
between 0.001 and 0.01; ***, P value less than 0.001. Unless indicated, all normalization 
and statistical tests compared to WT cells.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• D2HG production competes with reductive biosynthesis for NADPH in 
IDH1-mutant cells
•
2H tracing resolves L2HG and D2HG production pathways
• IDH1 mutation slows cell growth when biosynthetic NADPH demands are 
increased
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Figure 1. Metabolic Characterization of Isogenic IDH1-Expressing HT1080 Cell Lines
(A) Depiction of enzymatic activity present in each cell line.
(B) Relative intracellular abundance of glycolytic intermediates, TCA cycle metabolites, and 
amino acids (n = 6). Normalized to PB.
(C) Atom transition map of [U-13C5]glutamine for reductive and oxidative metabolism. 
Glutaminase and transamination of glutamate to aKG require concomitant amination of 
keto-acids (KA) to amino acids (AA) (e.g., Asp, Ala, Pro, Ser). Oxidative TCA flux leads to 
M+4 citrate. Reductive carboxylation of aKG leads to the M+5 citrate and subsequently M
+3 aspartate.
(D) Percentage of M+5 citrate from [U-13C5]glutamine in normoxia and hypoxia.
(E) Percentage of M+3 aspartate from [U-13C5]glutamine in normoxia and hypoxia.
In (B), (D), and (E), data are plotted as mean ± SEM. Unless indicated, all data represent 
biological triplicates. See also Figure S1.
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Figure 2. Tracing NAD(P)H Regeneration and 2HG Production in HT1080-IDH1 Cell Lines
(A) Atom transition map of [4-2H]glucose. The tracer labels cytosolic NADH through 
GAPDH, leading to downstream labeling through lactate dehydrogenase (LDH), malate 
dehydrogenase (MDH), and glycerol-3-phosphate dehydrogenase (Gly3PDH).
(B) Percentage M+1 label from [4-2H]glucose is not altered by IDH1 status.
(C) Relative intracellular abundance of 2-hydroxyglutarate is increased in R132C cells.
(D) Percentage M+1 2HG label from [4-2H]glucose and [3-2H]glucose.
(E) Depiction of L2HG and D2HG production by NAD(P)H.
In (B)–(D), data are plotted as mean ± SEM. Unless indicated, all data represent biological 
triplicates.
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Figure 3. D2HG Production and Secretion Increase NADPH Demands in IDH1+/R132C Cells
(A) NADPH consumption fluxes by lipid synthesis and 2HG production in fibrosarcoma 
panel.
(B) Atom transition map of [3-2H]glucose.
(C) Contribution of oxPPP to cytosolic NADPH in fibrosarcoma panel.
(D) 2HG abundance in parental HT1080 cells upon treatment with 10 mM AGI-5198.
(E) Contribution of oxPPP to cytosolic NADPH in parental HT1080 cells with 10 mM 
AGI-5198.
(F) Contribution of oxPPP to cytosolic NADPH in non-native IDH1-R132H engineered 
HCT116 cells.
In (A), (C), (E), and (F), data are plotted as mean ± 95% confidence interval (CI). 
*Statistical significance by non-overlapping confidence intervals. In (D), data are plotted as 
mean ± SEM. Unless indicated, all data represent biological triplicates. See also Figure S2.
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Figure 4. D2HG Production Limits NADPH for DNL in Lipid-Deficient Conditions
(A) Normalized cell number of fibrosarcoma panelafter 48 hr in delipidated conditions.
(B) Normalized cell number of HOG panel ectopically expressing IDH1 after 96 hr in 
delipidated conditions.
(C) Normalized molar palmitate synthesis flux infibrosarcoma panel.
(D) Normalized desaturation index (C18:1/C18:0) in fibrosarcoma panel.
(E) Percentage newly synthesized cholesterol after24 hr in control or delipidated conditions 
in fibrosarcoma panel.
(F) Extracellular glucose uptake and lactate effluxin fibrosarcoma panel.
(G) Normalized oxPPP flux in delipidated conditions in fibrosarcoma panel.
In (A)–(D), (F), and (G), data are plotted as mean ± SEM. In (E), data are plotted as mean 
± 95% CI. Unless indicated, all data represent biological triplicates. See also Figures S3 and 
S4.
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